Timeline Mitopure vs Longevity Box MitoSurge: Premium vs Value UA

Reviewed by SOMA HEALTH's Medical Research Team

Timeline Mitopure and Longevity Box MitoSurge are two ways of buying the same active compound, urolithin A, at two very different price tiers. This is a plain comparison of how they are positioned on dose, evidence framing, and cost, so you can decide what fits.

A note on neutrality: SOMA HEALTH is a competitor to both brands discussed here. We have tried to describe each fairly and to keep the focus on how to read a urolithin A label rather than on winning a sale. Prices and exact serving sizes change, so always check the current label before buying.

The one thing they have in common

Both products deliver urolithin A, and that matters more than any branding. Urolithin A is a gut postbiotic: your microbiome makes it from ellagitannins found in pomegranate, walnuts, and some berries, but only some people convert meaningful amounts, and many convert little or none. A supplement exists to deliver a standardized dose regardless of whether your gut is a good converter. So the real questions between two urolithin A products are dose per serving, format, third-party verification, and price, not whether one contains some secret different molecule.

Timeline Mitopure: the premium, research-forward option

Timeline is the company most associated with urolithin A, and Mitopure is its branded, standardized form of the ingredient. It is generally the flagship of the category: heavily tied to the published human research, sold in several formats including softgels and powder, and positioned at the premium end. As of this writing, Timeline's softgels list a 500 mg serving of urolithin A; check the current label, since serving sizes and formats are updated periodically. What you are paying more for is largely the brand's role in funding and being named in the clinical literature, plus polished formats. That is a legitimate thing to value, but it does not change the underlying molecule.

Longevity Box MitoSurge: the value option

MitoSurge from Longevity Box is positioned as a value alternative in the same category. Its label lists urolithin A at 500 mg per serving in a 60-capsule, roughly one-month supply. It aims to deliver a comparable per-serving dose of the same compound at a lower price tier by spending less on branding and clinical association. Again, confirm the current label figures before purchase, as they can change. The trade-off buyers accept with a value brand is usually less brand-funded research and a simpler product story, in exchange for cost.

Premium versus value: how to actually decide

Because the active compound is the same, the honest deciding factors are these. First, dose per serving: if two products list the same milligrams of urolithin A, that is the number that lines up with the human trials, which used 500 to 1,000 mg per day. Second, third-party testing: independent verification that the label matches the capsule is worth more than a prestigious name. Third, format and adherence: the best product is the one you will actually take every day, since the benefits in trials accrued over weeks to months. Fourth, price you can sustain, because this is a daily, ongoing supplement, not a one-time purchase. Our urolithin A dosage page breaks down the studied ranges, and urolithin A clinical studies summarizes the human trials both brands lean on.

What the human evidence supports (for either brand)

Whatever you buy, the evidence framing should be the same, because it describes the compound, not the label. The first-in-human study, Andreux and colleagues in Nature Metabolism (2019), reported urolithin A was safe and well tolerated up to 1,000 mg per day with a mitochondrial gene-expression signature. Singh and colleagues (Cell Reports Medicine, 2022) reported improvements in muscle strength and exercise performance in middle-aged adults over four months at 500 and 1,000 mg. Liu and D'Amico and colleagues (JAMA Network Open, 2022) reported muscle-endurance improvements in older adults. A 2025 Nature Aging trial supported immune-cell mitochondrial health in midlife adults over about 28 days. Laboratory work by Ryu and colleagues (Nature Medicine, 2016) showed mitophagy, lifespan extension in C. elegans, and muscle benefits in rodents; that work is preclinical and should not be read as a human outcome. And a 2024 systematic review in Ageing Research Reviews concluded the human evidence is still emerging. No brand, premium or value, gets to claim more than that.